See more : Mercell Holding ASA (MRCEL.OL) Income Statement Analysis – Financial Results
Complete financial analysis of QSAM Biosciences, Inc. (QSAM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of QSAM Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Karnalyte Resources Inc. (KRLTF) Income Statement Analysis – Financial Results
- Koss Corporation (KOSS) Income Statement Analysis – Financial Results
- BEC World Public Company Limited (BECVY) Income Statement Analysis – Financial Results
- Hong Kong Technology Venture Company Limited (1137.HK) Income Statement Analysis – Financial Results
- AGNC Investment Corp. (AGNCP) Income Statement Analysis – Financial Results
QSAM Biosciences, Inc. (QSAM)
About QSAM Biosciences, Inc.
QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer and related diseases. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was incorporated in 2004 and is headquartered in Austin, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 916.67K | 33.33K | 74.76K | 40.00K | 20.00K | 0.00 | 3.61K | 428.86K | 85.97K | 115.28K | 71.96K | 486.57K | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 372.94B | 354.00 | 0.00 | 63.30K | 7.17K | 5.80K | 2.46K | 1.04K | 292.96K | 77.61K | 139.54K | 116.01K | 761.56K | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -372.94B | 916.31K | 33.33K | 11.46K | 32.83K | 14.20K | -2.46K | 2.57K | 135.90K | 8.36K | -24.25K | -44.05K | -275.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 99.96% | 100.00% | 15.33% | 82.07% | 70.99% | 0.00% | 71.29% | 31.69% | 9.72% | -21.04% | -61.22% | -56.52% | 0.00% |
| Research & Development | 1.16M | 1.02M | 647.30K | 362.46K | 0.00 | 0.00 | 0.00 | 352.58K | 1.42M | 12.88K | 9.30K | 295.12K | 433.56K | 500.11K | 431.90K | 844.11K | 0.00 |
| General & Administrative | 1.78K | 4.44M | 10.39M | 961.94K | 2.08M | 1.61M | 1.34M | 1.73M | 1.98M | 4.52M | 44.82K | 1.55M | 1.98M | 0.00 | 0.00 | 2.43M | 74.60K |
| Selling & Marketing | -1,780.81B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 250.79K | 339.70K | 0.00 | 0.00 | 10.38K | 20.00K |
| SG&A | 2.78M | 4.44M | 10.39M | 961.94K | 2.08M | 1.61M | 1.34M | 1.73M | 1.98M | 4.52M | 44.82K | 1.81M | 2.32M | 4.04M | 2.17M | 2.44M | 94.60K |
| Other Expenses | 1,001.70B | 2,899.99B | -744.51K | -3.17M | 1.06M | 1.58M | -1.25M | 0.00 | 0.00 | 1.80K | 16.54K | 0.00 | 1.17M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.94M | 5.46M | 11.04M | 1.32M | 2.08M | 1.61M | 1.34M | 2.08M | 3.40M | 4.54M | 70.65K | 2.10M | 3.92M | 4.54M | 2.60M | 3.29M | 94.60K |
| Cost & Expenses | 3.94M | 5.46M | 11.04M | 1.32M | 2.08M | 1.61M | 1.40M | 2.09M | 3.40M | 4.54M | 71.69K | 2.39M | 4.00M | 4.68M | 2.71M | 4.05M | 94.60K |
| Interest Income | 0.00 | 74.39 | 44.17 | 490.40 | 540.88 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.00 | 17.74K | 17.74K | 20.67K | 0.00 |
| Interest Expense | 52.69K | 74.39K | 788.68K | 490.40K | 556.30K | 346.02K | 345.43K | 226.73K | 19.69K | 47.48K | 170.29K | 931.45K | 111.69K | 23.88K | 23.88K | 110.04K | 0.00 |
| Depreciation & Amortization | 36.30B | 36.30K | 236.56K | -3.17M | 1.06M | 199.00 | 23.13K | 71.27K | 84.25K | 22.55 | 16.54K | 64.49K | 66.96K | 54.54K | 73.24K | 52.17K | 0.00 |
| EBITDA | -3.94M | -5.41M | -11.93M | -5.33M | -93.05K | -1.58M | -1.30M | -1.98M | -3.30M | -480.59K | -4.54M | -1.90M | -2.70M | -2.67M | -4.57M | -2.44M | -94.60K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -11.32% | -3.12% | -3,419.48% | -4,940.10% | -16,502.75% | 0.00% | -1,428.60% | -443.14% | -4,472.86% | -3,590.50% | -3,632.34% | -719.54% | 0.00% |
| Operating Income | -3.94M | -5.46M | -11.04M | -1.32M | -1.16M | -1.58M | -1.33M | -2.05M | -3.38M | -4.54M | -68.08K | -2.70M | -3.91M | -4.57M | -2.64M | -3.56M | -94.60K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -126.76% | -4,733.21% | -1,772.52% | -5,118.28% | -16,924.00% | 0.00% | -1,886.97% | -628.70% | -4,550.76% | -3,962.23% | -3,671.83% | -731.75% | 0.00% |
| Total Other Income/Expenses | -450.62K | -20.11K | -935.80K | -4.50M | 479.99K | 1.18M | -1.39M | 549.59K | -151.22K | 1.02M | -4.68M | -200.17K | -200.17K | 543.89K | -2.31M | 127.87K | 0.00 |
| Income Before Tax | -4.39M | -5.48M | -11.98M | -5.82M | -681.98K | -397.26K | -2.72M | -1.50M | -3.54M | -4.75M | -238.37K | -2.90M | -4.02M | -4.95M | -2.51M | -3.66M | -94.60K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -74.40% | -1,191.78% | -3,635.96% | -3,744.31% | -17,680.11% | 0.00% | -6,606.82% | -675.37% | -4,680.67% | -4,291.97% | -3,494.12% | -751.60% | 0.00% |
| Income Tax Expense | -3.94K | 593.59K | 788.68K | -466.85K | 1.61M | 50.00K | -206.72K | -776.32K | 131.53K | 160.00K | 170.29K | 931.45K | 111.69K | 349.00 | 1.60K | 800.00 | 0.00 |
| Net Income | -4.39M | -6.07M | -12.77M | -5.35M | -2.30M | -397.26K | -2.72M | -1.50M | -3.54M | -4.75M | -238.37K | -2.90M | -4.02M | -4.95M | -2.52M | -3.66M | -94.60K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -250.49% | -1,191.78% | -3,635.96% | -3,744.31% | -17,680.11% | 0.00% | -6,606.82% | -675.37% | -4,680.67% | -4,292.27% | -3,496.35% | -751.77% | 0.00% |
| EPS | -2.88K | -3.45 | -16.13 | -38.77 | -44.16 | -7.97 | -58.25 | -52.67 | -212.02 | -3.05K | -6.61 | -2.44K | -3.85K | -4.63K | -2.20K | -2.94K | -75.92 |
| EPS Diluted | -2.88K | -3.45 | -16.13 | -38.77 | -44.16 | -7.97 | -58.25 | -52.67 | -212.02 | -3.05K | -6.61 | -2.44K | -3.85K | -4.63K | -2.20K | -2.94K | -75.92 |
| Weighted Avg Shares Out | 1.52K | 1.76M | 791.60K | 138.07K | 52.00K | 49.87K | 46.66K | 28.44K | 16.68K | 1.56K | 36.08K | 1.19K | 1.05K | 1.07K | 1.14K | 1.25K | 1.25K |
| Weighted Avg Shares Out (Dil) | 1.52K | 1.76M | 791.60K | 138.07K | 52.00K | 49.87K | 46.66K | 28.44K | 16.68K | 1.56K | 36.08K | 1.19K | 1.05K | 1.07K | 1.14K | 1.25K | 1.25K |
QSAM Biosciences Seeks to Expand Radiochemical Assets; Signs Option Agreement to License its Second Promising Cancer Therapy
Austin, Texas, March 17, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM) announced today that it has signed an Exclusive Option Agreement with IsoTherapeutics Group, LLC to allow the Company a 120-day period to perform diligence and negotiate a...
QSAM Biosciences Clarifies Recent Promotional and Trading Activities at the Request of OTC Markets
Austin, Texas;, Feb. 11, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM) (“QSAM” or the “Company”), today announced that it became aware on February 9, 2021 of certain promotional activities concerning its common stock through notification by Issuer Services...
Source: https://incomestatements.info
Category: Stock Reports